THYROCARENSEThyrocare Technologies LimitedMinimalNeutral
Announced Thu, 21 May · 10:49 IST

Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹475.00
prior close
₹472.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.2-0.2+0.5-1.7+3.7+5.7+7.2+7.4+9.9+12.0+14.7+17.9
Up moveDown movePending
AI summary

Docon Technologies Private Limited, the promoter of Thyrocare Technologies Limited, has submitted its annual disclosure under SEBI Takeover Code Regulation 31(4). The promoter group holds 60.93% stake in Thyrocare. During FY 2025-26, the promoter released its entire pledge on September 16, 2025 (3,76,56,092 shares), bringing encumbrance to zero. Subsequently, a fresh pledge was created on September 17, 2025 on 3,23,23,232 shares (60.99%), and additional pledge on December 2, 2025 bringing total encumbered shares to 9,69,69,696 (60.93%). This increase was due to a 2:1 bonus share allotment on December 1, 2025, requiring fresh encumbrance on newly allotted shares. No additional encumbrances were made beyond those already disclosed.

Likely market impact

The promoter maintaining 60.93% stake with encumbrance indicates continued control but with shares pledged as security. The pledge release and recreation shows active management of share-backed financing. Overall promoter holding remains strong above 60%, which is positive for control but the pledged portion may be a watch point for investors.